Similar articles for PMID: 11267622

Year	Number of Results
1960	1
1973	1
1974	1
1977	2
1978	1
1979	2
1980	2
1982	1
1983	1
1984	8
1985	4
1986	5
1987	5
1988	8
1989	11
1990	6
1991	19
1992	11
1993	9
1994	11
1995	5
1996	9
1997	10
1998	10
1999	16
2000	17
2001	12
2002	13
2003	7
2004	7
2005	7
2006	7
2007	15
2008	15
2009	11
2010	14
2011	11
2012	13
2013	13
2014	14
2015	6
2016	2
2017	6
2018	7
2019	4
2020	8
2021	7
2022	4
2024	0

1

Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking.

Rose JE, Behm FM, Westman EC. Rose JE, et al. Pharmacol Biochem Behav. 2001 Feb;68(2):187-97. doi: 10.1016/s0091-3057(00)00465-2. Pharmacol Biochem Behav. 2001. PMID: 11267622 Clinical Trial.

2

Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: a preliminary study.

McKee SA, Weinberger AH, Harrison EL, Coppola S, George TP. McKee SA, et al. Schizophr Res. 2009 Dec;115(2-3):317-24. doi: 10.1016/j.schres.2009.07.019. Epub 2009 Aug 22. Schizophr Res. 2009. PMID: 19700263 Free PMC article. Clinical Trial.

3

Mecamylamine does not precipitate withdrawal in cigarette smokers.

Eissenberg T, Griffiths RR, Stitzer ML. Eissenberg T, et al. Psychopharmacology (Berl). 1996 Oct;127(4):328-36. doi: 10.1007/s002130050094. Psychopharmacology (Berl). 1996. PMID: 8923568 Clinical Trial.

4

Mecamylamine acutely increases human intravenous nicotine self-administration.

Rose JE, Behm FM, Westman EC, Bates JE. Rose JE, et al. Pharmacol Biochem Behav. 2003 Sep;76(2):307-13. doi: 10.1016/j.pbb.2003.08.011. Pharmacol Biochem Behav. 2003. PMID: 14592683 Clinical Trial.

5

Nicotine-mecamylamine interactions.

Zevin S, Jacob P 3rd, Benowitz NL. Zevin S, et al. Clin Pharmacol Ther. 2000 Jul;68(1):58-66. doi: 10.1067/mcp.2000.108066. Clin Pharmacol Ther. 2000. PMID: 10945316 Clinical Trial.

6

Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia.

Weinberger AH, Sacco KA, Creeden CL, Vessicchio JC, Jatlow PI, George TP. Weinberger AH, et al. Schizophr Res. 2007 Mar;91(1-3):217-25. doi: 10.1016/j.schres.2006.12.007. Epub 2007 Feb 9. Schizophr Res. 2007. PMID: 17293085 Free PMC article. Clinical Trial.

7

Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal.

Teneggi V, Tiffany ST, Squassante L, Milleri S, Ziviani L, Bye A. Teneggi V, et al. Psychopharmacology (Berl). 2002 Nov;164(2):177-87. doi: 10.1007/s00213-002-1176-1. Epub 2002 Aug 27. Psychopharmacology (Berl). 2002. PMID: 12404080 Clinical Trial.

8

High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking.

Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, MacKinnon SV, Sirota AD, Kaplan GB. Rohsenow DJ, et al. Exp Clin Psychopharmacol. 2007 Feb;15(1):81-92. doi: 10.1037/1064-1297.15.1.81. Exp Clin Psychopharmacol. 2007. PMID: 17295587 Clinical Trial.

9

Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone.

Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV. Rose JE, et al. Clin Pharmacol Ther. 1994 Jul;56(1):86-99. doi: 10.1038/clpt.1994.105. Clin Pharmacol Ther. 1994. PMID: 8033499 Clinical Trial.

10

Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments.

Rose JE, Behm FM. Rose JE, et al. Nicotine Tob Res. 2004 Jun;6(3):523-32. doi: 10.1080/14622200410001696501. Nicotine Tob Res. 2004. PMID: 15203786 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

348 results

Results by year